Skip to main content
SpringerLink
Log in

Kutane Nebenwirkungen einer EGF-Rezeptor-Blockade und deren Management

Cutaneous side effects of EGF-receptor inhibition and their management

  • Übersicht
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Überexpression und Deregulation des „epidermal growth factor“- (EGF-)Rezeptors spielt eine wichtige Rolle bei der Entstehung und Progression vieler Karzinome. Antagonisten des EGF-Rezeptors wie der blockierende Antikörper Cetuximab und niedermolekulare Tyrosinkinaseinhibitoren wie Gefitinib und Erlotinib werden zunehmend in der Tumortherapie eingesetzt. Der EGF-Rezeptor wird auch in normaler Haut und Epithelien exprimiert. Kutane Nebenwirkungen sind bei der therapeutischen Blockade des EGF-Rezeptors häufig, und ihr Schweregrad scheint mit dem Ansprechen der Therapie zu korrelieren. In dieser Arbeit werden die kutanen Nebenwirkungen dargestellt und Vorschläge zu deren Management gemacht.

Abstract

The receptor of the epidermal growth factor (EGF-receptor) plays a role in the pathogenesis of many human carcinomas. Recent strategies in anti-tumor therapy target the EGF-receptor, e.g., by the EGF-receptor blocking monoclonal antibody cetuximab or by small molecules inhibiting the tyrosine kinase activity of the EGF-receptor, such as gefitinib and erlotinib. The EGF-receptor is also expressed in normal human skin; in clinical trials with different EGF-receptor inhibitors, cutaneous side effects were common. We report on cutaneous side effects of EGF-receptor blockade, in particular acneiform lesions, xerosis and paronychia, and discuss their management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Averbuch SD (2002) Lung cancer prevention: retinoids and the epidermal growth factor receptor-a phoenix rising? Clin Cancer Res 8:1–3

    PubMed  Google Scholar 

  2. Baselga J, Rischin D, Ranson M et al. (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292–4302

    Article  PubMed  Google Scholar 

  3. Boucher KW, Davidson K, Mirakhur B et al. (2002) Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 47:632–633

    PubMed  Google Scholar 

  4. Braun-Falco M, Holtmann C, Lordick F, Ring J (2005) Follikuläre Arzneimittelreaktion auf Cetuximab. Eine häufige Nebenwirkung bei der Therapie metastasierter kolorektaler Karzinome. Hautarzt online, publiziert 1. Juli 2005

  5. Bunn PA Jr,Franklin W (2002) Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 29:38–44

    Article  Google Scholar 

  6. Busam KJ, Capodieci P, Motzer R et al. (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169–1176

    Article  PubMed  Google Scholar 

  7. Chang GC, Yang TY, Wang NS et al. (2003) Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients. J Formos Med Assoc 102:407–411

    PubMed  Google Scholar 

  8. Crombet T, Osorio M, Cruz T et al. (2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22:1646–1654

    Article  PubMed  Google Scholar 

  9. Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  PubMed  Google Scholar 

  10. Forsythe B, Faulkner K (2004) Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 27:1081–1092

    PubMed  Google Scholar 

  11. Gutzmer R, Werfel T, Mao R et al. (2005) Successful treatment of acneiform skin lesions associated with cetuximab therapy with oral isotretinoin. Br J Dermatol 153:849–851

    Article  PubMed  Google Scholar 

  12. Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59:21–26

    Article  Google Scholar 

  13. Herbst RS, LoRusso PM, Purdom M, Ward D (2003) Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 4:366–369

    PubMed  Google Scholar 

  14. Jacot W, Bessis D, Jorda E et al. (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151:238–241

    Article  PubMed  Google Scholar 

  15. Kimyai-Asadi A, Jih MH (2002) Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 138:129–131

    Article  PubMed  Google Scholar 

  16. Kowalzick L, Lohse C, Ziegler H, Busch FW (2004) Schwere Akne unter Therapie eines metastasierten kolorektalen Karzinoms mit monoklonalem Anti-EGF-Rezeptor-Antikörper Cetuximab (Erbitux). Aktuelle Dermatologie 30:474–477

    Article  Google Scholar 

  17. Lee MW, Seo CW, Kim SW et al. (2004) Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 84:23–26

    Article  PubMed  Google Scholar 

  18. Mendelsohn J (1992) Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J Natl Cancer Inst Monogr 13:125–131

    PubMed  Google Scholar 

  19. Monti M, Mancini LL, Ferrari B et al. (2003) Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab. J Clin Oncol 21:4651–4653

    Article  PubMed  Google Scholar 

  20. Perez-Soler R (2003) Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt) 17:23–28

    Google Scholar 

  21. Perez-Soler R (2004) HER1/EGFR targeting: refining the strategy. Oncologist 9:58–67

    Article  PubMed  Google Scholar 

  22. Rowinsky EK, Schwartz GH, Gollob JA, et al. (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003–3015

    Article  PubMed  Google Scholar 

  23. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208

    Article  PubMed  Google Scholar 

  24. Shah NT, Kris MG, Pao W et al. (2005) Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23:165–174

    Article  PubMed  Google Scholar 

  25. Shimizu M, Suzui M, Deguchi A et al. (2004) Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin Cancer Res 10:1130–1140

    Article  PubMed  Google Scholar 

  26. Soulieres D, Senzer NN, Vokes EE et al. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77–85

    Article  PubMed  Google Scholar 

  27. Susman E (2004) Rash correlates with tumour response after cetuximab. Lancet Oncol 5:647

    Article  Google Scholar 

  28. Van Doorn R, Kirtschig G, Scheffer E et al. (2002) Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 147:598–601

    Article  PubMed  Google Scholar 

  29. Walon L, Gilbeau C, Lachapelle JM (2003) Acneiform eruptions induced by cetuximab. Ann Dermatol Venereol 130:443–446

    Google Scholar 

  30. Yano S, Kondo K, Yamaguchi M et al. (2003) Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23:3639–3650

    PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Venerologie der Medizinischen Hochschule Hannover

    R. Gutzmer, T. Werfel, A. Kapp & J. Elsner

  2. Klinik und Poliklinik für Dermatologie und Venerologie, Medizinische Hochschule, Ricklinger Straße 5, 30449 , Hannover

    R. Gutzmer

Authors
  1. R. Gutzmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Werfel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Kapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Elsner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Gutzmer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gutzmer, R., Werfel, T., Kapp, A. et al. Kutane Nebenwirkungen einer EGF-Rezeptor-Blockade und deren Management. Hautarzt 57, 509–513 (2006). https://doi.org/10.1007/s00105-005-1033-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-005-1033-3

Schlüsselwörter

Keywords

Search

Navigation